Business Wire

ITER Organization Chooses Bertin Technologies to Design a Density Interferometer Polarimeter

Share

Bertin Technologies , a subsidiary of CNIM Group , has received a contract from ITER Organization for the preliminary design of the “Density Interferometer Polarimeter” (DIP), a complex optical diagnostic system that measures plasma density during nuclear fusion reactions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005118/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

“Density Interferometer Polarimeter” (DIP) Copyright Bertin Technologies

This is a key component of the tokamak reactor’s future diagnostic instruments. The purpose of the DIP will be to help control plasma by measuring the density of the electrons in order to ensure its stability and obtain an optimal energy yield.

Optical instrumentation design and manufacturing, such as the DIP technology, are key areas of excellence at Bertin Technologies, the French leader of industrial innovation for this field. Collaborating with the ITER program since 2009, through contracts with the ITER Organization at Cadarache, Fusion For Energy in Barcelona and Princeton Physics Plasma Laboratory in the USA, Bertin Technologies has developed itself in instrumentation designed to analyze fusion plasma, contributing to the control and safety of experiments as well as acquiring parametric data that will be used by physicians. Building on its unique experience and expertise, Bertin’s objective for the coming years is to take charge of other aspects of complete diagnostics for ITER, from the design phase to the installation on site.

This contract showcases Bertin teams’ expertise in the field of Big Science.

ABOUT BERTIN TECHNOLOGIES

BERTIN TECHNOLOGIES, subsidiary of CNIM Group, relies on its long history of innovation to develop, produce and market innovative systems and equipment worldwide. Among its 700 employees, there are 2/3 engineers and high-level managers. The company is active worldwide and its turnover amounts to nearly 100 million euros in 2017.

Based on his experience in the Megajoule Laser program, Bertin has positioned himself since 2009 on instrumentation intended to analyze the fusion plasma to contribute to the conduct and safety of ITER Organization's experiments, but also to acquire the parameters that will be operated by physicians. With the acquisition in 2017 of Winlight, a French company specializing in the design and manufacturing of components and systems for high performance optics, Bertin strengthens its presence in the field of Big Science (research reactors, synchrotrons, telescopes) and for major defense and space programs, with customers in Europe, the United States and Asia.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Frédérique Vigezzi
frederique.vigezzi@gootenberg.fr
Tel : + 33 1 43 59 29 84

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists23.4.2024 14:00:00 EEST | Press release

Incyte (Nasdaq:INCY) and Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders, have entered into a definitive agreement under which Incyte has agreed to acquire Escient, including EP262, a first-in-class, potent, highly selective, once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2) and EP547, a first-in-class oral MRGPRX4 antagonist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423725958/en/ “As a company dedicated to innovation and the discovery of transformative medicines, we are excited to add EP262 and EP547 to our portfolio. This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “EP262 and EP547 are complementary additions to our portfolio, prov

REPLY S.p.A.: Shareholders’ Meeting Approves the 2023 Financial Statements23.4.2024 13:43:00 EEST | Press release

The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] today approved the Financial Statements for the financial year 2023, confirming the distribution of a gross dividend of €1.00 per share. The dividend will be paid on 22 May 2024, with dividend date set on 20 May 2024 (record date on 21 May 2024). 2023 Financial Statement The Reply Group closed the 2023 financial year with a consolidated turnover of €2,118.0 million, recording a 12.0% increase compared to €1,891.1 million in 2022. Consolidated EBITDA was €325.1 million, up 3.5% compared to €340.3 million recorded in 2022 (growth yoy is 20% net of the release of COVID funds accounted in 2022). EBIT, from January to December, was €292.7 million, up 2.5% compared to €285.5 million recorded in 2022 (growth yoy is 22.7% net of the release of COVID funds accounted in 2022). The Group net profit was at €186.7 million. In 2022, the corresponding figure was €191.0 million. The Shareholders’ Meeting also adopted the following reso

Eaton’s Mobility Group Chosen to Supply Electromechanical Variable Valve Actuation Technology to Great Wall Motor23.4.2024 13:30:00 EEST | Press release

Intelligent power management company Eaton today announced it has been chosen to supply an electromechanical actuation system (EMAS) that can deliver an early intake valve closing (EIVC) to the China-based automaker Great Wall for use in a line of hybrid-electric vehicles (HEV). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423118914/en/ Eaton’s electromechanical actuation system (EMAS) can be easily integrated into a valvetrain and the cylinder head space and controlled by a simple electric actuator. (Photo: Business Wire) “Emissions regulations are driving the adoption of new technologies by our global customers,” said Alessio Lorenzon, global engineering manager, Valves, Eaton’s Mobility Group. “We’re proud to supply Great Wall with our variable valve actuation technology which, in combination with vehicle hybridization, will improve fuel economy in their newest hybrid passenger vehicle lineup.” The Eaton EMAS is a di

Rasa Recognized as a Representative Vendor in Gartner® Market Guide for Conversational AI Solutions23.4.2024 13:03:00 EEST | Press release

Rasa, a leader in generative conversational AI, proudly announces its recognition as a Representative Vendor in the Gartner® Market Guide for Conversational AI Solutions. Rasa believes this acknowledgment highlights its pivotal role in the future of AI-driven communication and its commitment to delivering innovative solutions that enhance business interactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423570629/en/ Rasa has been recognized as a Representative Vendor in the Gartner Market Guide for Conversational AI Solutions, highlighting its role in transforming business operations through AI-driven conversations. This acknowledgment underscores the importance of evaluating the Conversational AI market to enhance customer interactions, achieve cost efficiencies, and elevate customer service. (Graphic: Business Wire) Melissa Gordon, CEO of Rasa, shares her thoughts: “We think recognition from Gartner® validates our

BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer23.4.2024 13:00:00 EEST | Press release

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use. “Tislelizumab is foundational for BeiGene’s solid tumor portfolio and has demonstrated its potential across multiple tumor types, including NSCLC, in which there remains a significant unmet need at all stages of the disease,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “Today’s EC authorization marks the second in the region for tislelizumab, with both NSCLC and locally advanced or metastatic esophageal squamous cell carcinoma now approved in the European Union. Second-line use in ESCC was also approved just weeks ago by the U.S. Food and Drug Administration, putting us well on our way to fulfilling our commitment to bring this innovative therapy to many more patients around the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye